Aprea advances two Phase 1 cancer programs but faces cash crunch, runway into Q1 2026

Aprea Therapeutics, Inc. (NASDAQ: APRE)

Short take - Clinical-stage oncology biotech focused on synthetic lethality (WEE1 inhibitor APR-1051; ATR inhibitor ATRN-119). Management is advancing two Phase‑1 programs and reports limited cash runway: ~ $16.5M on hand, continued quarterly losses and a formal going‑concern disclosure. Below are the key facts, what's happening inside the company, and quick positives/negatives from the income statement.

Key facts & stats (from Form 10‑Q, quarter ended June 30, 2025)
- Cash & cash equivalents: $16,532,199 (restricted cash $40,673; total cash + restricted cash $16,572,872).
- Total assets: $17,309,710; Total stockholders' equity: $13,414,681.
- Accumulated deficit: $(328,213,401).
- Series A convertible preferred stock (temporary equity): $727,361 (31,194 shares outstanding at 6/30/25).
- Common shares issued & outstanding (reported 6/30/25): 5,752,175 (weighted‑avg shares - six months: 6,038,845).
- Three months ended 6/30/25 - Grant revenue: $118,111; R&D: $1,912,213; G&A: $1,593,671; Net loss: $(3,238,870); Net loss per share (basic & diluted): $(0.53).
- Six months ended 6/30/25 - Grant revenue: $280,574; Total operating expenses: $7,753,929; Net loss: $(7,171,529); Net loss per share: $(1.19).
- Cash used in operating activities (six months): $(6,761,917).
- Financing cash (six months) - net proceeds from ATM / share issuances: $440,728 (includes $459,019 proceeds from common stock issuance).
- Potential common share equivalents excluded as anti‑dilutive: 3,058,804 (options, warrants, convertible preferred conversion).
- Management disclosure: "substantial doubt exists about ability to continue as a going concern"; management expects current cash to fund operations into the first quarter of 2026 but not through a full 12 months from issuance.

What's happening inside the company - operations & progress
- Clinical progress: APR‑1051 (oral WEE1 inhibitor) and ATRN‑119 (oral macrocyclic ATR inhibitor) are both in Phase 1. Management expects open‑label safety/efficacy data in H2 2025 and to determine RP2D in H1 2026 for both programs.
- R&D focus: increasing investment in ATRN‑119 clinical work (YTD R&D up vs prior year due to ABOYA‑119 activity); APR‑1051 escalation also ongoing. Company retains preclinical DDR program work.
- Funding activity: small ATM sales in 2025 produced ~ $0.4M; the bulk of prior financing came from March 2024 private placement (~$16M gross). Series A preferred partially converted in April 2025 (25,033 shares converted).
- Grants: NIH grant revenue declined vs prior year (six months: $280,574 vs $942,143 in 2024), reducing a small non‑dilutive revenue source.
- Corporate controls: management and CFO concluded disclosure controls were effective; no material legal proceedings reported.

Income statement - positives
- Operating expense control (quarterly): total operating expenses fell Q2 2025 vs Q2 2024 (3,505,884 vs 4,408,498), driven by lower R&D and G&A in the quarter.
- R&D prioritization: spending shifted into the ATRN‑119 program where management sees clinical progress - explains increased YTD R&D but focused use of limited resources.
- Other income: interest income and occasional foreign exchange gains provide modest offset when present (though interest income has declined vs prior year).

Income statement - negatives / risks
- Persistent losses: six‑month net loss of $(7,171,529); accumulated deficit > $(328M).
- Grant revenue falling: NIH grant receipts down materially (six months down ~$0.66M), weakening non‑dilutive support.
- Cash burn: operating cash outflow ~ $6.8M over six months (~$1.1M/month), leaving limited runway - company says cash likely only covers into Q1 2026 and management has concluded substantial doubt about going concern.
- Financing dependence: small ATM proceeds in 2025 (~$0.4M) are insufficient to close the funding gap; future capital raises (equity, debt, collaborations) expected and will likely dilute existing holders given outstanding warrants/options and convertible preferred.
- FX exposure: foreign currency losses (Swedish subsidiary translation/remeasurement) contributed to other losses (six months foreign currency loss $(80,927)).

Operational & capital‑market watch items
- Upcoming catalysts: open‑label safety/efficacy data from Phase 1 cohorts expected H2 2025; RP2D decisions expected H1 2026 - these are the near‑term value inflection points.
- Cash runway & financing: primary near‑term risk. Company needs additional financing before or around Q1 2026 unless costs materially slow. Monitor ATM activity, warrant exercises, strategic partnerships or a larger equity/debt raise.
- Dilution potential: >3.0M potential common equivalents outstanding (options, warrants, convertible preferred as converted) - a future raise could be dilutive.
- Clinical execution: timely patient enrollment and positive safety/PK signals will be critical to unlock tranche warrant exercises (March 2024 warrants have price/trigger conditions tied to RP2D and stock price milestones).
- Regulatory / cost risk: further clinical requirements, slower enrollment, or adverse safety findings would materially increase cash needs.

Bottom line (straightforward)
Aprea (NASDAQ: APRE) is advancing two Phase‑1 synthetic‑lethality oncology programs and has operational progress to report. Financially, the company is cash‑constrained: ~$16.5M on hand, ongoing monthly cash burn, a going‑concern disclosure and an explicit need to raise additional capital within the next several quarters. Positive trial readouts in H2 2025 would materially change the outlook; absent such catalysts, expect continued financing activity and dilution risk.

If you follow the ticker, watch upcoming clinical data, management capital‑raise moves, monthly burn trends, and any partnership announcements - those will determine whether the company turns development progress into sustainable funding or returns to the market for dilutive financing.